A Phase III, open-label trial of TMC435 in combination with peginterferon alpha-2a and ribavirin for HCV genotype-1 infected subjects who participated in the placebo group of a Phase II/III TMC435 study (C201, C205, C206, C208, C216 or HPC3007), or who received short-term (up to 14 days) direct-acting antiviral treatment for hepatitis C infection in a selected Tibotec-sponsored Phase I study.
Phase of Trial: Phase III
Latest Information Update: 13 Apr 2016
At a glance
- Drugs Simeprevir (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Registrational; Therapeutic Use
- Sponsors Janssen R&D Ireland
- 07 Apr 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 06 Mar 2014 Status changed from recruiting to active, no longer recruiting as reported by the ClinicalTrials.gov record.
- 27 Sep 2013 Last checked against United Kingdom Clinical Research Network.